Frontline therapy of acute promyelocytic leukemia: Randomized comparison of ATRA and intensified chemotherapy versus ATRA and anthracyclines.
Eva LengfelderDennis GörlichDaniel NowakKarsten SpiekermannClaudia HaferlachUtz KrugKarl-Anton KreuzerJan BraessChristoph SchliemannHans-Walter LindemannHeinz A HorstXaver SchielMichael FlasshoveAnna HechtSusanne SchnittgerStephanie SchneiderBernhard WörmannWolf-Karsten HofmannWolfgang E BerdelEike BormannCristina SauerlandThomas BüchnerWolfgang Hiddemannnull nullPublished in: European journal of haematology (2017)
The small number of patients limits the reliability of conclusions. With these restrictions, the outcomes of both approaches were similar and show the limitations of ATRA and chemotherapy. The HD ara-C-containing regimen was associated with a lower relapse rate in high-risk APL.
Keyphrases
- end stage renal disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- locally advanced
- liver failure
- open label
- peritoneal dialysis
- prognostic factors
- bone marrow
- double blind
- type diabetes
- patient reported outcomes
- radiation therapy
- intensive care unit
- respiratory failure
- clinical trial
- placebo controlled
- acute respiratory distress syndrome
- skeletal muscle
- free survival
- extracorporeal membrane oxygenation